Tarcine BioMed, a subsidiary of BAHEAL Pharmaceutical Group, has been successfully selected by the Beijing Association for Science and Technology "Thousands of People Entering Thousands of Enterprises" Science and Technology Innovation Public Service Prom
发布时间：2024-12-31 浏览次数：393次 作者：
Recently, Tarcine BioMed（Beijing) Inc. (hereinafter referred to as "Tarcine BioMed"), a subsidiary of BAHEAL Pharmaceutical Group, successfully entered the 2024 Beijing Association for Science and Technology's "Thousand People Entering Thousand Enterprises" Science and Technology Innovation Public Service Promotion Plan, and successfully obtained certificates and financial support.
The "Thousands of People Entering Thousands of Enterprises" Science and Technology Innovation Public Service Promotion Plan is organized and implemented by the Beijing Association for Science and Technology. With the participation of industry special commissioners, it focuses on scientific and technological innovation needs such as industrial chain supplementation, strengthening, and extension, and provides in-depth scientific and technological innovation services to enterprises. The service content includes various forms of services such as scientific and technological consulting that plays a key role in the industry where the enterprise is located, developing products that are leading in the industry, and aiming to explore and establish a collaborative innovation mechanism that deeply integrates industry, academia, and research.
For this project application, under the guidance of Director Wang Hongtian from the Allergy Department of Beijing Shijitan Hospital, Capital Medical University, who serves as the industry special correspondent, Tarcine BioMed has relied on the project of "Development of Omalizumab Blood Concentration and Its Anti-Drug Antibody Detection Kit," a macromolecular therapeutic drug. Through collaborative efforts and joint problem-solving, they effectively addressed the technical challenge of detection interference and completed the development of the monitoring method.
The Department of Allergic Reactions at Beijing Shijitan Hospital, Affiliated to Capital Medical University, was established in 1982. In 2005, it became the only independent department of allergy in a municipal hospital in Beijing, and has gradually developed into a national key clinical specialty that ranks among the top in the country. Omalizumab is an important therapeutic drug for allergic asthma, and its concentration in the blood is closely related to treatment efficacy. Therefore, reasonably monitoring drug concentration and anti-drug antibody concentration has important guiding significance for improving patient treatment outcomes and reducing medical costs.
The close collaboration between Tarcine BioMed and Shijitan Hospital this time is a concrete manifestation of medical-enterprise cooperation, and a microcosm of Baheal Pharmaceutical Group's efforts to optimize medical scenarios through technological innovation. In the future, Tarcine BioMed will continue to vigorously develop a macromolecular drug monitoring platform, and contribute to the precise administration of macromolecular drugs by overcoming difficulties through multiple channels and cooperation models.
